bioAffinity Technologies will present CyPath Lung clinical and veteran-focused research at NAVREF, including previously reported results showing 92% sensitivity, 87% specificity and 99% negative predictive value. The presentations matter to investors because they cover clinical use, an enrolling military and veteran study, and the diagnostic’s stated role alongside other evaluations.

Key Highlights

  • NAVREF’s annual conference will take place September 27, 2026, in Arlington, Virginia.
  • The FlowPath Lung study is enrolling veterans and military personnel and has support from the John P. Murtha Cancer Center Research Program.
  • Presentations will address CyPath Lung’s clinical and research use in veteran and military populations.

The event is scheduled for September 27, 2026, in Arlington, Virginia. The presentations will address the diagnostic’s use in clinical practice and research involving veteran and military populations.

CyPath Lung Cases and FlowPath Study bioAffinity Technologies, Inc.

(NASDAQ: BIAF) says the approach accelerated diagnosis, supported difficult clinical discussions and helped avoid unnecessary invasive procedures. A separate poster covers the ongoing FlowPath™ Lung research study evaluating the test in veteran and military populations. FlowPath Lung uses the same test as commercially available CyPath Lung, with the name reserved for the research programme. The study is currently enrolling, while the John P. Murtha Cancer Center Research Program is providing support and partial funding.

At-Home Collection and Clinical Performance

CyPath Lung’s at-home sputum collection is highlighted as a way for participants to provide specimens without travelling to a VA medical facility. The test uses flow cytometry and automated analysis to identify cell populations in sputum associated with malignancy.